|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.655 USD | +1.34% |
|
+2.30% | -26.04% |
Company Valuation: Altimmune, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 363.1 | 808.4 | 604.4 | 512.8 | 394 | 509.5 | - | - |
| Change | - | 122.62% | -25.23% | -15.16% | -23.16% | 29.3% | - | - |
| Enterprise Value (EV) 1 | 363.1 | 697.3 | 469.3 | 380.9 | 350.2 | 188 | 337.4 | 509.5 |
| Change | - | 92.02% | -32.7% | -18.84% | -8.04% | -46.34% | 79.5% | 51.02% |
| P/E | -3.9x | -9.09x | -6.78x | -5.38x | -3.61x | -3.8x | -3.38x | -3.08x |
| PBR | - | - | - | 4.22x | - | - | - | - |
| PEG | - | 0.4x | 0.82x | 0.3x | 0.1x | 0.1x | -0.3x | -0.32x |
| Capitalization / Revenue | 82.3x | -11,889x | 1,419x | 25,640x | 9,611x | 111,737x | - | 199x |
| EV / Revenue | 82.3x | -10,255x | 1,102x | 19,044x | 8,543x | 41,218x | - | 199x |
| EV / EBITDA | -3.77x | -7.93x | -4.92x | -3.7x | -3.71x | -1.47x | -2.09x | -2.75x |
| EV / EBIT | -4.25x | -7.95x | -5.62x | -3.69x | -3.71x | -1.56x | -2.33x | -3.25x |
| EV / FCF | -4.02x | -11.1x | -6.19x | -4.77x | -5.19x | -1.89x | -2.89x | -3.57x |
| FCF Yield | -24.9% | -8.99% | -16.2% | -21% | -19.3% | -52.8% | -34.6% | -28% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.35 | -1.81 | -1.66 | -1.34 | -1 | -0.69 | -0.7754 | -0.85 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.41 | -0.068 | 0.426 | 0.02 | 0.041 | 0.00456 | - | 2.562 |
| EBITDA 1 | -96.36 | -87.94 | -95.45 | -102.9 | -94.48 | -127.5 | -161.6 | -185.6 |
| EBIT 1 | -85.54 | -87.74 | -83.51 | -103.2 | -94.49 | -120.8 | -144.8 | -156.6 |
| Net income 1 | -97.09 | -84.71 | -88.45 | -95.06 | -88.09 | -113.9 | -141.8 | -157.2 |
| Net Debt 1 | - | -111.1 | -135.2 | -131.9 | -43.8 | -321.6 | -172.1 | - |
| Reference price 2 | 9.160 | 16.450 | 11.250 | 7.210 | 3.610 | 2.620 | 2.620 | 2.620 |
| Nbr of stocks (in thousands) | 39,644 | 49,146 | 53,729 | 71,125 | 109,155 | 194,474 | - | - |
| Announcement Date | 3/15/22 | 2/28/23 | 3/27/24 | 2/27/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.8x | 41218.26x | -1.47x | - | 510M | |
| 32x | 8.3x | 25.1x | 0.06% | 54.54B | |
| 16.43x | 4.93x | 10.71x | 1.83% | 43.86B | |
| -17.51x | 4x | -6.98x | -.--% | 22.63B | |
| -36.18x | 11.93x | -34.8x | -.--% | 20.7B | |
| 19.54x | 3.8x | 9.87x | -.--% | 15.84B | |
| 20.6x | 4.16x | 13.77x | -.--% | 14.83B | |
| 16.47x | 4.75x | 11.13x | -.--% | 13.1B | |
| -444.13x | 30.23x | -3370.59x | -.--% | 12.66B | |
| -72.96x | 7.37x | -66.11x | -.--% | 11.56B | |
| Average | -46.95x | 4,129.77x | -340.94x | 0.21% | 21.02B | |
| Weighted average by Cap. | -20.54x | 107.79x | -199.69x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALT Stock
- Valuation Altimmune, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition